Zynex Appoints New Independent Board Member

News provided by

Mar 06, 2018, 01:14 ET

ENGLEWOOD, Colo., March 6, 2018 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced the appointment of Joshua R. Disbrow to its Board of Directors and Audit Committee.

Thomas Sandgaard, Zynex Founder, Chairman and Chief Executive Officer said: "I am very pleased with the appointment of Josh as our new independent board member, his business and healthcare industry experience will provide us the depth and resources required for the company to continue on its growth trajectory as well as complying with the requirements of a senior exchange."

Mr. Disbrow has been in the life sciences industry for over twenty years across pharmaceuticals, diagnostics, and medical devices. Currently, Mr. Disbrow serves as the Chairman and Chief Executive Officer of Aytu BioScience, Inc. ("Aytu"NASDAQ: AYTU), a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology. Prior to forming Aytu, Mr. Disbrow was the Chief Operating Officer of Ampio Pharmaceuticals ("Ampio", a NASDAQ traded company) and led the Luoxis Diagnostics subsidiary "Luoxis"). Luoxis was merged into Aytu in April 2015 following Luoxis' development of the technology behind the company's MiOXSYS in vitro diagnostic platform. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals ("Arbor").

Mr. Disbrow began as Arbor's second employee and oversaw the commercialization of the company's first product, scaling the commercial organization to over 150 people across sales, marketing, payer markets, distribution, and national accounts. In less than four years, Arbor grew from a company without any product revenues to a company with net sales of $127 million. Prior to joining Arbor, he was the Director of Marketing at LipoScience (a NASDAQ traded company), a cardiovascular in vitro diagnostic company. Mr. Disbrow also served in sales management at Cyberonics (Now LivaNova plc, a NASDAQ traded company), a medical device company commercializing implantable neuromodulation devices. He started his career at Glaxo Wellcome (now GlaxoSmithKline plc), holding positions in both sales and marketing. He has a Master of Business Administration from Wake Forest University and Bachelor of Science in Management from North Carolina State University.

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2017 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.

Contact: Zynex, Inc. (303) 703-4906

Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
[email protected]

SOURCE Zynex, Inc.